

Champions Indications of Interest – Sep 2021

<p>Drug resistant & rare tumors</p> <p><u>Specimen requirements:</u></p> <ul style="list-style-type: none"> • 2-4 18-gauge core needle biopsies OR • Surgical resections (no minimum tissue size) • Matched blood <u>optional</u> 	<ul style="list-style-type: none"> • Treatment resistant metastatic breast cancer <ul style="list-style-type: none"> ○ Treated with PARP inhibitors (e.g. Olaparib) ○ HER2+ targeted therapy (e.g. Trastuzumab, T-DM1, Enhertu) • Treatment resistant ovarian cancer <ul style="list-style-type: none"> ○ Treated with PARP inhibitors (e.g. Olaparib) • Treatment resistant gastric cancer <ul style="list-style-type: none"> ○ HER2+ cancer showing progression on HER2 targeted therapy • Treatment resistant prostate, pancreatic cancer <ul style="list-style-type: none"> ○ Treated with PARP inhibitors (e.g. Olaparib) • Molecularly characterized and/or treatment resistant NSCLC <ul style="list-style-type: none"> ○ EGFR mutant (C797S/T790/L858R, C797S, Exon20ins) ○ HER2 Exon 20 mutant ○ KRAS mutant (G12C, G13C) ○ NSCLC that showed progression on Next-Gen TKI (e.g. Osimertinib) ○ NSCLC that showed progression on selective RET inhibitors (e.g. Selpercatinib) • Mesothelioma • Adenoid Cystic Carcinoma • Esophageal cancer • Hepatocellular carcinoma • Gastrointestinal Stromal Tumor (GIST) • Thyroid cancer • Post-Immuno-Oncology Therapy with matched blood (any)
---	---

<p>Solid tumor surgical resections for autologous program</p> <p><u>Specimen requirements:</u></p> <ul style="list-style-type: none"> • Minimum 0.5g tissue, 2-3g ideal < 0.5g acceptable if matched blood (10-30ml) can be also provided 	<p>INDICATIONS: (no specific mutations or treatment history)</p> <table border="0"> <tr> <td data-bbox="724 998 1428 1377"> <ul style="list-style-type: none"> • Breast cancer • Prostate cancer • Melanoma • Gastric cancer • Pancreatic cancer • Colorectal cancer (metastatic sites only) • Ovarian cancer </td> <td data-bbox="1428 998 1997 1377"> <ul style="list-style-type: none"> • Small Cell Lung Cancer (SCLC) • Non-Small Cell Lung Cancer (NSCLC) • Head and Neck • Renal Cell Carcinoma • Endometrial cancer • Bladder cancer </td> </tr> </table>	<ul style="list-style-type: none"> • Breast cancer • Prostate cancer • Melanoma • Gastric cancer • Pancreatic cancer • Colorectal cancer (metastatic sites only) • Ovarian cancer 	<ul style="list-style-type: none"> • Small Cell Lung Cancer (SCLC) • Non-Small Cell Lung Cancer (NSCLC) • Head and Neck • Renal Cell Carcinoma • Endometrial cancer • Bladder cancer
<ul style="list-style-type: none"> • Breast cancer • Prostate cancer • Melanoma • Gastric cancer • Pancreatic cancer • Colorectal cancer (metastatic sites only) • Ovarian cancer 	<ul style="list-style-type: none"> • Small Cell Lung Cancer (SCLC) • Non-Small Cell Lung Cancer (NSCLC) • Head and Neck • Renal Cell Carcinoma • Endometrial cancer • Bladder cancer 		